Impact of rivaroxaban on point-of-care assays

Fontana, Pierre; Alberio, Lorenzo; Angelillo-Scherrer, Anne; Asmis, Lars; Korte, Wolfgang; Mendez, Adriana; Schmid, Pirmin; Stricker, Hans; Studt, Jan-Dirk; Tsakiris, Dimitrios A; Wuillemin, Walter A; Nagler, Michael

doi:10.1016/j.thromres.2017.03.019

Scientific article

English

Impact of rivaroxaban on point-of-care assays

ContributorsFontana, Pierre; Alberio, Lorenzo; Angelillo-Scherrer, Anne; Asmis, Lars; Korte, Wolfgang; Mendez, Adriana; Schmid, Pirmin; Stricker, Hans; Studt, Jan-Dirk; Tsakiris, Dimitrios A; Wuillemin, Walter A; Nagler, Michael

Published inThrombosis research, vol. 153, p. 65-70

Publication date2017

Abstract

Point-of-care testing (POCT) is regularly used to assess haemostasis in various clinical settings. The impact of rivaroxaban on those POCT is still elusive. We aimed to study the effects of rivaroxaban on most commonly used POCT assays.

Affiliation entities

Faculté de médecine / Section de médecine clinique / Département de médecine

Research groups

Plaquettes et antithrombotiques (13)

Citation (ISO format)

FONTANA, Pierre et al. Impact of rivaroxaban on point-of-care assays. In: Thrombosis research, 2017, vol. 153, p. 65–70. doi: 10.1016/j.thromres.2017.03.019

Article (Published version)

Identifiers

PID : unige:94322
DOI : 10.1016/j.thromres.2017.03.019
PMID : 28343143

Journal ISSN0049-3848

472views

0downloads

Creation21/04/2017 15:54:00

First validation21/04/2017 15:54:00

Update03/02/2025 11:26:05

Status update03/02/2025 11:26:05

Last indexation03/02/2025 11:34:10

Archive ouverte UNIGE

Impact of rivaroxaban on point-of-care assays

Point-of-care testing (POCT) is regularly used to assess haemostasis in various clinical settings. The impact of rivaroxaban on those POCT is still elusive. We aimed to study the effects of rivaroxaban on most commonly used POCT assays.

Technical informations